Navigation Links
Sun Pharmaceutical Industries, Inc. Issues Nationwide Voluntary Recall of One Lot of Nimodipine Capsules due to Crystallization of the Fill Material
Date:9/4/2012

CRANBURY, N.J., Sept. 4, 2012 /PRNewswire/ -- Sun Pharmaceutical Industries, Inc. (Sun Inc) announced today that it is voluntarily recalling from users one lot of Nimodipine Capsules, 30 mg, marketed by Caraco Pharmaceutical Laboratories, Ltd. Sun Inc. commenced the recall as a precautionary measure due to the presence of crystals of nimodipine within the capsule solution of this lot as identified by a customer complaint.  No adverse events have been reported at this time.

Nimodipine Capsules, 30 mg, are used to decrease problems due to subarachnoid hemorrhage (bleeding in the brain). Nimodipine capsules 30 mg are clear yellow solution filled in oblong opaque light yellow softgel capsules, imprinted "135" in black ink. The product is supplied in unit dose blisters of 30 and 100, as described below. The affected product was distributed nationwide between January 19, 2012 and April 24, 2012.

The crystallization of the nimodipine fill material in the capsule could adversely affect the product's bioavailability. Although clinical health implications are unknown, use of the product when the nimodipine has crystallized in the capsule may be of great clinical significance. The product may no longer be bioequivalent and may potentially affect patients who are being treated for a medical emergency.

As a precautionary measure, Sun Inc is recalling the following lot numbers to the consumer level to minimize any potential risk to patients

Lot Number: 3305.039A, NDC Number: 57664-135-65 (Unit Dose Blisters of 100 (25x4))
Lot Number: 3305.039B, NDC Number: 57664-135-64 (Unit Dose Blisters of 30 (5x6))

The recalled capsules were manufactured for Sun Inc by Pharmaceutics International, Inc. This recall is being conducted with the knowledge of the Food and Drug Administration.

Patients and healthcare providers using Nimodipine Capsules, 30 mg, with one of the above lot numbers should discontinue use of the product and should contact the following number for more information about the recall:  Inmar Inc. at 1-800-967-5952 (Option 1 then Option 3). Representatives are available Monday through Friday, 8 AM to 5 PM EST.

Patients using Nimodipine Capsules, 30 mg, who have medical questions, should contact their healthcare provider for additional instructions or guidance.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, by regular mail, or by fax.


'/>"/>
SOURCE Sun Pharmaceutical Industries, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
2. Brand new Solid Form Co-Crystals and Amorphous Focus Morning at the Pharmaceutical Co-Crystals and Amorphous Material 2012 Summits
3. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
4. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
5. Health Outcome Liaisons Improve Decision Making for Pharmaceutical Industry Challenged by Reform and Compliance Issues
6. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
7. Sihuan Pharmaceutical Announces 2012 Interim Results
8. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market
9. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
10. Isis Pharmaceuticals Demonstrates The Potential Of Single-Stranded RNA-Like Antisense Technology To Activate The RNAi Pathway
11. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016   Mallinckrodt Pharmaceuticals ... specialty pharmaceutical company, today announced that it received a ... Equality Index (CEI), a national benchmarking survey and report ... bisexual and transgender (LGBT) workplace equality, administered by the ... of 517 major U.S. businesses which also earned top ...
(Date:12/5/2016)... INTRODUCTION Since the ... as a crucial class of pharmacological interventions responsible ... are also used for prophylactic purposes in patients ... patients undergoing chemotherapy). However, the inappropriate use of ... rapidly accelerated an evolutionary response of antibiotic drug ...
(Date:12/5/2016)... Special purpose needles are used in target specific drug deliveries ... organs or lumps and are available in the market with ... special purpose needles is showing a steady growth owing to ... special purpose needles market is projected to expand at a ... expected to be valued at US$ 17,261.5 million by the ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... 06, 2016 , ... GrekTek LLC, ( http://www.grektek.com ) an ... http://kck.st/2g3a1so ) for the HealthyWatch, a new device to help patients manage their ... watch while sharing these events with caregivers in real time. , ...
(Date:12/6/2016)... ... December 06, 2016 , ... Keeping Gift Season Safe, In a season stacked ... and age-appropriate for their recipients. This is the idea behind Safe Toys and Gifts ... items that would make good gifts for children. For companies that produce goods that ...
(Date:12/6/2016)... Overland Park, KS (PRWEB) , ... December 06, 2016 , ... ... online retailers of Mobility Scooters . , Mobility Scooters give freedom to people ... and balance problems. Still others may be facing a long period of rehabilitation after ...
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) was ... for their industry leading training methods that engage their associates and link their ... global elite in employer-sponsored training and development programs. , “The 2017 Training Top ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward ... to announce the arrival of the newest Sciton laser in January 2017. The ... use tunable non-ablative and ablative wavelengths for exceptional results. Outperforming more traditional lasers, ...
Breaking Medicine News(10 mins):